Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.
Breast Cancer
DRUG: Anastrazole|DRUG: Gefitinib
To determine and compare changes in proliferation marker at 16 weeks in the treatment groups
Tumour response, safety and tolerability, pharmacokinetics, pharmacokinetics and dynamics, oestradiol levels, mastectomy rate.|Comparison of WHO and RECIST criteria,|Exploratory biomarker studies involving genomics, metabolomics and proteomics.
The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.